Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: A Gynecologic Oncology Group study

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 4, 2010, Pages 351.e1-351.e8

  Kunos, Charles ^a   Ali, Shamshad ^b   Abdul Karim, Fadi W ^a   Stehman, Frederick B ^c   Waggoner, Steven ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cervix cancer; chemoradiation; hysterectomy histopathology

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PELVIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RECURRENT DISEASE; RISK FACTOR; SURVIVAL TIME; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CARCINOMA; CONTROLLED STUDY; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 77957334056     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.05.005     Document Type: Article

References (27)

1. H.M. Keys, B.N. Bundy, and F.B. Stehman Radiation therapy with and witout extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group Gynecol Oncol 89 2003 343 353
2. H.M. Keys, B.N. Bundy, and F.B. Stehman Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 340 1999 1154 1161
3. F.B. Stehman, S. Ali, and H. Keys Radiation therapy with or without weekly cisplatin for bulky stage IB cervical carcinoma: follow-up of a Gynecologic Oncology Group trial Am J Obstet Gynecol 197 2007 503 e1-6
4. F. Landoni, A. Maneo, and A. Colombo Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer Lancet 350 1997 535 540
5. P. Benedetti-Panici, S. Greggi, and A. Colombo Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cancer: results from the Italian multicenter randomized study J Clin Oncol 20 2002 179 188
6. G.F. Zannoni, V.G. Vellone, and A. Carbone Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment Int J Gynecol Pathol 27 2008 274 281
7. P.W. Grigsby, B.A. Siegel, F. Dehdashti, and D.G. Mutch Posttherapy surveillance monitoring of cervical cancer by FDG-PET Int J Radiat Oncol Biol Phys 55 2003 907 913
8. E. Schwartz, U.K. Freese, and L. Gissmann Structure and transcription of human papillomavirus sequences in cervical carcinoma cells Nature 314 1985 111 114
9. F.C. Eilber, G. Rosen, and J. Eckardt Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas J Clin Oncol 19 2001 3203 3209
10. P. Picci, L. Sangiorgi, B.T. Rougraff, J.R. Neff, R. Casadei, and M. Campanacci Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma J Clin Oncol 12 1994 2699 2705
11. J.H. Zunino, and J.O. Johnston Prognostic value of histologic tumor necrosis assessment in osteogenic sarcoma of bone Am J Orthop 29 2000 369 372
12. J.M. Bland, and D.G. Altman The logrank test BMJ 328 2004 1073
13. J. Crowley A note on some recent likelihoods leading to the log rank test Biometrika 61 1974 533 538
14. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
15. D. Cox Regression models and life tables (with discussion) J R Stat Soc 34 1972 187 220
16. P. Therasse, S. Arbuck, and E. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
17. S.L. Hillman, M.W. An, and M.J. O'Connell Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation J Clin Oncol 27 2009 3205 3210
18. L.K. Shankar, J.M. Hoffman, and S. Bacharach Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials J Nucl Med 47 2006 1059 1066
19. C. Suzuki, H. Jaconson, and T. Hatschek Radiologic measurements of tumor response to treatment: practical approaches and limitations Radiographics 28 2008 329 344
20. P. Shield, B. Daunter, and R. Wright Post-irradiation cytology of cervical cancer patients Cytopathology 3 1992 167 182
21. P.G. Rose, S. Ali, and E. Watkins Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 2804 2810
22. P.J. Eifel, K. Winter, and M. Morris Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01 J Clin Oncol 22 2004 872 880 (Pubitemid 41103599)
23. W.A. Peters 3rd, P.Y. Liu, and R.J. Barrett 2nd Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix J Clin Oncol 18 2000 1606 1613
24. C.W. Whitney, W. Sause, and B.N. Bundy Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study J Clin Oncol 17 1999 1339 1348
25. R. Lanciano, A. Calkins, and B.N. Bundy Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group Study J Clin Oncol 23 2005 8289 8295
26. C. Kunos, S. Chiu, J. Pink, and T. Kinsella Modulating radiation resistance in cervical cancer by inhibiting ribonucleotide reductase with Triapine® (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) Radiation Res 172 2009 666 676
27. C.A. Kunos, S. Waggoner, and V. von Gruenigen Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer Clin Cancer Res 16 2010 1298 1306